Company insider dossier

Exelixis Inc insider intelligence

EXEL filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
26/100

Concentrated distribution

93/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
10 Aug 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 15 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 10 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction26Concentrated distribution
Confidence93Deep evidence
Named insiders15participating in the tape
Controlled events17directional common-share events
Acquisition value$497.5Knormalized amount
Disposal value$23.4Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

56.5051.0245.5340.0534.57 Disposal · 10 Aug 2026 · $526.5KDisposal · 1 Jun 2026 · $492.0KDisposal · 1 Jun 2026 · $198.4KAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedAcquisition · 27 May 2026 · Not reportedDisposal · 26 May 2026 · $2.2MDisposal · 20 May 2026 · $1.6MAcquisition · 18 May 2026 · Not reportedDisposal · 18 May 2026 · Not reportedDisposal · 18 May 2026 · $1.7MDisposal · 18 May 2026 · $332.6KDisposal · 15 May 2026 · $6.6MDisposal · 15 May 2026 · $2.1MDisposal · 15 May 2026 · $1.7MDisposal · 15 May 2026 · $1.6MDisposal · 15 May 2026 · $327.6KDisposal · 7 May 2026 · $2.7MDisposal · 7 May 2026 · $949.2KAcquisition · 7 May 2026 · $407.9KDisposal · 7 May 2026 · $373.6KAcquisition · 7 May 2026 · $89.6KDisposal · 6 May 2026 · Not reported
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
51.24 USD
One-week move
-5.2%
Four-week move
-8.4%
Fair-value gap
+49.0%
Trend signal
Active
Relative strength
-0.7

Directional balance

Controlled event mix

11.8%acquisition
Acquisition events
2
Disposal events
15
Net value
-$22.9M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

201 Jun
008 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
110 Aug
017 Aug

Named participants

Insider conviction by person

FREIRE, MARIA CDirector612 events
HEYMAN, TOMAS J.Director500 events
JOHNSON, DAVID EDWARDDirector500 events
OLIVER, BOBDirector500 events
PAPADOPOULOS, STELIOSDirector500 events
SMITH, JULIEDirector500 events
BECKERLE, MARY CDirector393 events
ECKHARDT, SUE GAILDirector281 events
POSTE, GEORGEDirector281 events
WYSZOMIERSKI, JACK LDirector281 events
MORRISSEY, MICHAELDirector, President and CEO281 events
AFTAB, DANAEVP, Research and Development252 events

Evidence quality

Security and transaction context

Common equity29
Equity compensation0
Options and derivatives3
Other securities0

Role architecture

Who is participating

Director20
CEO and chair4
Other or unspecified4
Finance leadership2
Other executive2

Transaction evidence

Auditable EXEL filing ledger

Showing 1 to 30 of 32.

BECKERLE, MARY CDirector
DisposalCommon equity
9812 sharesCommon Stock
$526.5KDirectional evidence
ECKHARDT, SUE GAILDirector
DisposalCommon equity
9812 sharesCommon Stock
$492.0KDirectional evidence
WYSZOMIERSKI, JACK LDirector
DisposalCommon equity
3925 sharesCommon Stock
$198.4KDirectional evidence
BECKERLE, MARY CDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
ECKHARDT, SUE GAILDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
FREIRE, MARIA CDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
HEYMAN, TOMAS J.Director
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
JOHNSON, DAVID EDWARDDirector
AcquisitionOptions and derivatives
19133 sharesOption (right to buy)
Not reportedContext evidence
OLIVER, BOBDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
PAPADOPOULOS, STELIOSDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
POSTE, GEORGEDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
SMITH, JULIEDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
WYSZOMIERSKI, JACK LDirector
AcquisitionCommon equity
8367 sharesCommon Stock
Not reportedContext evidence
AFTAB, DANAEVP, Research and Development
DisposalCommon equity
43451 sharesCommon Stock
$2.2MDirectional evidence
HALEY, PATRICK J.EVP, Commercial
DisposalCommon equity
32110 sharesCommon Stock
$1.6MDirectional evidence
MORRISSEY, MICHAELDirector, President and CEO
AcquisitionCommon equity
124047 sharesCommon Stock
Not reportedContext evidence
MORRISSEY, MICHAELDirector, President and CEO
DisposalCommon equity
124047 sharesCommon Stock
Not reportedContext evidence
SENNER, CHRISTOPHER J.EVP and CFO
DisposalCommon equity
34901 sharesCommon Stock
$1.7MDirectional evidence
HEFTI, BRENDASVP and General Counsel
DisposalCommon equity
6625 sharesCommon Stock
$332.6KDirectional evidence
MORRISSEY, MICHAELDirector, President and CEO
DisposalCommon equity
128497 sharesCommon Stock
$6.6MDirectional evidence
SENNER, CHRISTOPHER J.EVP and CFO
DisposalCommon equity
40892 sharesCommon Stock
$2.1MDirectional evidence
HALEY, PATRICK J.EVP, Commercial
DisposalCommon equity
33265 sharesCommon Stock
$1.7MDirectional evidence
AFTAB, DANAEVP, Research and Development
DisposalCommon equity
30578 sharesCommon Stock
$1.6MDirectional evidence
HEFTI, BRENDASVP and General Counsel
DisposalCommon equity
6411 sharesCommon Stock
$327.6KDirectional evidence
BECKERLE, MARY CDirector
DisposalOptions and derivatives
3856 sharesOption (right to buy)
Not reportedContext evidence
FREIRE, MARIA CDirector
DisposalOptions and derivatives
20634 sharesOption (right to buy)
Not reportedContext evidence
POSTE, GEORGEDirector
DisposalCommon equity
60000 sharesCommon Stock
$2.7MDirectional evidence
FREIRE, MARIA CDirector
DisposalCommon equity
20634 sharesCommon Stock
$949.2KDirectional evidence
FREIRE, MARIA CDirector
AcquisitionCommon equity
20634 sharesCommon Stock
$407.9KDirectional evidence
BECKERLE, MARY CDirector
DisposalCommon equity
7712 sharesCommon Stock
$373.6KDirectional evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context